Lisa Pieri researcher
Pieri, Lisa
VIAF ID: 307327061 (Personal)
Permalink: http://viaf.org/viaf/307327061
Preferred Forms
- 100 0 _ ‡a Lisa Pieri ‡c researcher
- 200 _ 1 ‡a Pieri ‡b , Lisa
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques | |
The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics | |
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value | |
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients | |
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. | |
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. | |
Concomitant occurrence of BCR-ABL and JAK2V617F mutation | |
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis | |
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. | |
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms | |
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression | |
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. | |
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele | |
Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. | |
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study | |
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. | |
Improving prognostic tools in systemic mastocytosis: Insights from mutations | |
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology | |
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. | |
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia | |
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis | |
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. | |
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. | |
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera | |
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. | |
Masked polycythemia vera (mPV): results of an international study | |
MR Imaging in non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. | |
The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. | |
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis | |
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea | |
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. | |
Redox-modulazione γ-glutamiltransferasi-dipendente di bersagli molecolari critici in cellule di melanoma metastatico : dissertazione / presentata da Lisa Pieri ; coordinatore: Mario Comporti ; tutore: Alfonso Pompella | |
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. | |
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. | |
Study of new molecular alterations on Philadelphia-negative chronic myeloproliferative neoplasms / Lisa Pieri ; tutore: Alessandro M. Vannucchi | |
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms | |
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis | |
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis. | |
Treatment options for essential thrombocythemia and polycythemia vera |